Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I. Haddad, Ranee Mehra, Makoto Tahara et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 96
Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).Robert I. Haddad, Ranee Mehra, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2017Cited by 56
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G. Pfister, Joshua Bauml, Robert I. Haddad et al.|Cancer Medicine|2022Cited by 48
Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)Tanguy Y. Seiwert, Laura Q.M. Chow, Răzvan Cristescu et al.|Cancer Research|2018Cited by 38